中源协和股价小幅波动，研报指估值偏高但经营现改善

Core Viewpoint - The stock price of Zhongyuan Qihua has shown slight fluctuations, with a recent price of 25.77 yuan as of February 11, 2026, reflecting a 1.70% increase over the past five days but a 6.36% decline over the past twenty days [1] Group 1: Stock Performance - The trading activity is relatively low, with a turnover rate of only 0.60% on February 11, 2026, and an average daily trading volume of approximately 1.2 billion yuan [1] - The pharmaceutical and biotechnology sector has seen a slight decline of 0.32%, indicating that the company's stock performance is slightly better than the industry average [1] Group 2: Institutional Insights - According to a valuation analysis by Securities Star on February 10, 2026, the relative valuation range for Zhongyuan Qihua is between 21.33 and 23.58 yuan, with an accuracy rating of C, suggesting that the current stock price is relatively high [2] - The company's competitive moat within the industry is considered average, with revenue of 1.092 billion yuan and a net profit of 108 million yuan for the first three quarters of 2025, indicating pressure on profitability [2] - The market's expectation for long-term policy benefits related to stem cells is reflected in a price-to-earnings ratio (TTM) of 161.33 times [2] Group 3: Financial Report Analysis - The third-quarter report for 2025 shows a year-on-year decline in both revenue and profit, although the revenue decline in the third quarter has narrowed to 6.82%, and the net profit attributable to the parent company has slightly increased by 3.74%, indicating marginal improvement in operational conditions [3] - The gross profit margin remains high at 69.22%, and the net cash flow from operating activities is 223 million yuan, demonstrating stable core business capabilities [3]